Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas

Area of Science:

• Oncology
• Biochemistry
• Dermatology

Background:

• Osteonectin, also known as secreted protein, acidic and rich in cysteine (SPARC), is a glycoprotein implicated in tissue mineralization, cell-matrix interactions, and angiogenesis.
• Emerging evidence suggests osteonectin's potential role in tumor invasion and metastasis across various malignancies.

Purpose of the Study:

• To investigate the correlation between osteonectin expression and clinical outcomes in thin cutaneous malignant melanomas.
• To determine if osteonectin expression serves as a prognostic marker for melanoma progression and survival.

Main Methods:

• Retrospective analysis of 188 thin cutaneous melanomas (≤0.75 mm), with 12 progressing cases selected for study.
• Immunohistochemistry used to assess osteonectin expression in tumor cells of selected cases and 24 matched controls.
• Kaplan-Meier method and log rank test employed to analyze progression-free survival, disease-specific survival, and correlations with clinicopathologic parameters.

Main Results:

• Osteonectin immunoreactivity was detected in 63.8% of cases; 50% showed partial staining (1-50% of cells) and 13.8% showed diffuse staining (>50% of cells).
• Osteonectin expression significantly correlated with an increased risk of progression (P = .01), incidence of distant metastases (P = .005), and poorer survival (P = .03).
• No significant correlation was observed between osteonectin expression and other clinicopathologic features such as age, sex, histotype, or tumor growth phase.

Conclusions:

• Osteonectin expression is a significant predictor of clinical outcome in thin cutaneous melanomas.
• Elevated osteonectin levels are associated with adverse prognostic factors, including tumor progression and metastasis.
• Further research into osteonectin's role may lead to novel therapeutic strategies for melanoma.